EFFICACY AND SAFETY OF LONG-TERM EVOLOCUMAB USE IN ASIAN VERSUS OTHER SUBJECTS: THE FOURIER TRIAL

There are concerns that Asian people respond differently to some medications. We evaluated the efficacy and safety of evolocumab use in the FOURIER trial among participants of Asian versus other backgrounds. The effects of adding evolocumab (either 140 mg subcutaneously every 2 weeks or 420 mg